Business Standard

Don’t miss the latest developments in business and finance.

Mylan gets DCGI nod to launch HIV drug Avonza in India

Product is recommended by WHO as alternative first-line regimen for HIV/AIDS: Mylan

Bs_logoPharma
IPA states that of the 20 companies in the alliance, 14 comply with all pricing norms. These 14 had been accused of overcharging in the cases of 145 formulations
Press Trust of India New Delhi
Last Updated : Aug 08 2017 | 2:41 PM IST
US based drug firm Mylan today said its Indian arm has received nod from the country's drug regulator DCGI to market its antiretroviral drug Avonza.

Mylan Pharmaceuticals Private Ltd, a subsidiary of Mylan N V, has received marketing authorisation from the Drug Controller General of India (DCGI) for its antiretroviral drug Avonza, the company said in a statement.

The product is recommended by the World Health Organisation (WHO) as an alternative first-line regimen for people being treated for HIV/AIDS, it added.

More From This Section

"Developing Avonza and bringing it to patients with HIV in India is a continuation of our strong and sustained commitment to expanding access to affordable, high quality ARVs," Mylan President Rajiv Malik said.

Avonza will be available to patients at a cost that is lower than that of other current first-line ARVs, he added.

The company's comprehensive ARV portfolio includes 14 active pharmaceutical ingredients and 50 finished dosage forms in first-line, second-line and paediatric formulations, Mylan said.

Also Read

First Published: Aug 08 2017 | 2:41 PM IST

Next Story